Durvalumab, a PD-L1 inhibitor, as an adjuvant treatment following definitive CRT for unresectable stage III NSCLC, has the most robust evidence of survival benefits among combination therapies of radiotherapy and immunotherapy for lung cancer. The gene discussed is CD274; the disease is lung carcinoma.